المؤلفون: Lu S; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn., Wu L; Department of Thoracic Medical Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Jian H; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China., Chen Y; Department of Oncology, Jilin Cancer Hospital, Changchun, China., Wang Q; Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, China., Fang J; Department of Thoracic Medical Oncology, Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing, China., Wang Z; Department of Thoracic Medical Oncology, Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing, China., Hu Y; Department of Thoracic Medical Oncology, Hubei Cancer Hospital, Wuhan, China., Sun M; Department of Oncology, Jinan Central Hospital affiliated to Shandong University, Jinan, China., Han L; Department of Oncology, Xuzhou Central Hospital, Xuzhou, China., Miao L; Department of Respiratory Medicine, Nanjing University Mdical School affiliated to Nanjing Drum Tower Hospital, Nanjing, China., Ding C; Department of Respiratory Medicine, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China., Cui J; Department of Oncology, Jilin University First Hospital, Changchun, China., Li B; Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China., Pan Y; Department of Oncology, Anhui Provincial Hospital, Hefei, China., Li X; Department of Oncology, Zhengzhou University First Affiliated Hospital, Zhengzhou, China., Ye F; Department of Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China., Liu A; Department of Oncology, Nanchang University Second Affiliated Hospital, Nanchang, China., Wang K; Department of Respiratory Medicine, Sichuan University West China Hospital, Chengdu, China., Cang S; Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, China., Zhou H; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China., Sun X; Department of Biostatistics and Information, Innovent Biologics, Suzhou, China., Ferry D; Department of Oncology Medical Strategy, Eli Lilly and Company, New York, NY, USA., Lin Y; Eli Lilly and Company, Indianapolis, IN, USA., Wang S; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China., Zhang W; Department of Biostatistics and Information, Innovent Biologics, Suzhou, China., Zhang C; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China.

المصدر: The Lancet. Oncology [Lancet Oncol] 2022 Sep; Vol. 23 (9), pp. 1167-1179. Date of Electronic Publication: 2022 Jul 28.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Biosimilar Pharmaceuticals*/therapeutic use , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics, Adult ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Cisplatin ; Disease Progression ; ErbB Receptors/genetics ; Humans ; Pemetrexed/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Tyrosine/therapeutic use

المؤلفون: Gong R; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Lin W; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Gao A; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Liu Y; Provincial Key Laboratory of Radio-Oncology, Shandong Cancer Hospital and Institute, Jinan, China., Li J; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Sun M; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Chen X; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Han S; Genetic and Molecular Diagnostic Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Men C; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Sun Y; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China., Liu J; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.

المصدر: Cancer science [Cancer Sci] 2019 Dec; Vol. 110 (12), pp. 3663-3676. Date of Electronic Publication: 2019 Nov 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE

مواضيع طبية MeSH: Promoter Regions, Genetic*, Carcinoma, Non-Small-Cell Lung/*pathology , Forkhead Transcription Factors/*physiology , Lung Neoplasms/*pathology , Protein-Lysine 6-Oxidase/*genetics, Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/mortality ; Cell Line, Tumor ; Cell Proliferation ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/secondary ; Male ; Middle Aged ; Neoplasm Invasiveness ; Prognosis ; Protein-Lysine 6-Oxidase/physiology

المؤلفون: Han Y; Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China; School of Medicine, Shandong University, Jinan, Shandong 250012, China., Liu J; Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China., Sun M; Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China., Zhang Z; School of Medicine, Shandong University, Jinan, Shandong 250012, China., Liu C; Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China., Sun Y; Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China.

المصدر: Disease markers [Dis Markers] 2016; Vol. 2016, pp. 7643981. Date of Electronic Publication: 2016 Jan 21.

نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 8604127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1875-8630 (Electronic) Linking ISSN: 02780240 NLM ISO Abbreviation: Dis Markers Subsets: MEDLINE

مواضيع طبية MeSH: Polymorphism, Single Nucleotide*, Carcinoma, Non-Small-Cell Lung/*drug therapy , DNA-Binding Proteins/*genetics , Endonucleases/*genetics , Lung Neoplasms/*drug therapy , Organoplatinum Compounds/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Asian People/genetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Middle Aged ; Predictive Value of Tests ; Prospective Studies ; Survival Analysis